JP2014513953A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513953A5 JP2014513953A5 JP2014506589A JP2014506589A JP2014513953A5 JP 2014513953 A5 JP2014513953 A5 JP 2014513953A5 JP 2014506589 A JP2014506589 A JP 2014506589A JP 2014506589 A JP2014506589 A JP 2014506589A JP 2014513953 A5 JP2014513953 A5 JP 2014513953A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- region
- bms3h
- antibody polypeptide
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 28
- 229920001184 polypeptide Polymers 0.000 claims 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims 27
- 150000001413 amino acids Chemical class 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 230000004927 fusion Effects 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000000104 Arthus reaction Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000020446 Cardiac disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000022555 Genital disease Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 208000007466 Male Infertility Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034038 Parotitis Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161477904P | 2011-04-21 | 2011-04-21 | |
| US61/477,904 | 2011-04-21 | ||
| PCT/US2012/034519 WO2012145673A1 (en) | 2011-04-21 | 2012-04-20 | Antibody polypeptides that antagonize cd40 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017000493A Division JP2017099391A (ja) | 2011-04-21 | 2017-01-05 | Ｃｄ４０を拮抗する抗体ポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014513953A JP2014513953A (ja) | 2014-06-19 |
| JP2014513953A5 true JP2014513953A5 (https=) | 2015-04-23 |
| JP6114256B2 JP6114256B2 (ja) | 2017-04-12 |
Family
ID=46000407
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506589A Expired - Fee Related JP6114256B2 (ja) | 2011-04-21 | 2012-04-20 | Ｃｄ４０を拮抗する抗体ポリペプチド |
| JP2017000493A Pending JP2017099391A (ja) | 2011-04-21 | 2017-01-05 | Ｃｄ４０を拮抗する抗体ポリペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017000493A Pending JP2017099391A (ja) | 2011-04-21 | 2017-01-05 | Ｃｄ４０を拮抗する抗体ポリペプチド |
Country Status (35)
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201909840T4 (tr) | 2011-03-11 | 2019-07-22 | Beth Israel Deaconess Medical Ct Inc | Anti-CD40 antikorları ve kullanımları. |
| HUE038848T2 (hu) * | 2011-04-21 | 2018-11-28 | Bristol Myers Squibb Co | CD40-antagonista antitest polipeptidek |
| ES2709654T3 (es) | 2011-04-29 | 2019-04-17 | Apexigen Inc | Anticuerpos anti-CD40 y métodos de uso |
| SMT202000091T1 (it) | 2011-10-13 | 2020-05-08 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40l |
| KR102270618B1 (ko) | 2012-10-30 | 2021-06-30 | 아펙시젠, 인코포레이티드 | 항-cd40 항체 및 사용 방법 |
| EP3113796A1 (en) | 2014-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
| CN116059378A (zh) | 2014-12-10 | 2023-05-05 | 明尼苏达大学董事会 | 用于治疗疾病的遗传修饰的细胞、组织和器官 |
| IL308212A (en) | 2015-01-20 | 2024-01-01 | Igm Biosciences Inc | Tumor necrosis factor-α receptor binding molecules and their uses |
| MA41459A (fr) * | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| TW201713700A (zh) * | 2015-05-27 | 2017-04-16 | 台灣泰福生技股份有限公司 | 抗ｇｌｙｐｉｃａｎ-３抗體及其用於診斷及治療癌症之用途 |
| CN107810198B (zh) | 2015-05-29 | 2021-09-03 | 艾伯维公司 | 抗cd40抗体及其用途 |
| BR112018004296B1 (pt) | 2015-09-04 | 2020-05-05 | Primatope Therapeutics Inc | anticorpos anti-cd40 humanizados e usos dos mesmos |
| WO2017160975A1 (en) | 2016-03-16 | 2017-09-21 | Bristol-Myers Squibb Company | Methods of diagnosing and treating lupus |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| CN110546164B (zh) | 2016-11-11 | 2023-10-20 | 锦湖Ht株式会社 | 特异性结合cd40的抗体及其用途 |
| US20200347143A1 (en) | 2016-12-19 | 2020-11-05 | Glenmark Pharmaceuticals S.A. | Novel tnfr agonists and uses thereof |
| SG11201908744PA (en) * | 2017-03-23 | 2019-10-30 | Univ Pennsylvania | Anti-c5a antibodies and uses thereof |
| KR102840867B1 (ko) | 2017-05-24 | 2025-07-30 | 에이엘에스 테라피 디벨럽먼트 인스티튜트 | 치료용 항-cd40 리간드 항체 |
| US11220550B2 (en) | 2017-05-25 | 2022-01-11 | Bristol-Myers Squibb Company | Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity |
| US20200148779A1 (en) * | 2017-05-25 | 2020-05-14 | Bristol-Myers Squibb Company | MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH |
| JP2020522495A (ja) | 2017-05-30 | 2020-07-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物 |
| AU2018278051A1 (en) | 2017-06-01 | 2020-01-30 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| BR112021009835A2 (pt) | 2018-11-30 | 2021-08-17 | Jiangsu Hengrui Medicine Co., Ltd. | anticorpo anti-cd40, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos |
| US20240254248A1 (en) | 2018-11-30 | 2024-08-01 | Jiangsu Hengrui Medicine Co., Ltd. | Cd40 antibody pharmaceutical composition and use thereof |
| CN113993893A (zh) * | 2019-02-01 | 2022-01-28 | 拉法医疗有限公司 | 新cd40结合抗体 |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| US20210032356A1 (en) * | 2019-08-02 | 2021-02-04 | Eastern Virginia Medical School | Method for treating seizures |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| IL293640A (en) | 2019-12-20 | 2022-08-01 | Amgen Inc | CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| US11862306B1 (en) | 2020-02-07 | 2024-01-02 | Cvs Pharmacy, Inc. | Customer health activity based system for secure communication and presentation of health information |
| CA3172092A1 (en) * | 2020-04-23 | 2021-10-28 | David Cheresh | Compositions and methods for treating cancer |
| JP7523586B2 (ja) | 2020-05-18 | 2024-07-26 | ブリストル－マイヤーズ スクイブ カンパニー | 改善された薬物動態特性を有する抗体変異体 |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| AU2022303363A1 (en) | 2021-06-29 | 2024-01-18 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| US12234294B2 (en) | 2021-11-05 | 2025-02-25 | Kiniksa Pharmaceuticals, Gmbh | Pharmaceutical composition of a humanized anti-CD40 antibody |
| CN114149508B (zh) * | 2021-11-25 | 2023-04-28 | 苏州普乐康医药科技有限公司 | 一种结合cd40l的融合蛋白及其应用 |
| JP2025508076A (ja) | 2022-03-08 | 2025-03-21 | アレンティス・セラピューティクス・アクチェンゲゼルシャフト | Ｔ細胞の利用能を向上させるための抗クローディン－１抗体の使用 |
| WO2023198194A1 (en) * | 2022-04-15 | 2023-10-19 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-cd40 antibodies and uses thereof |
| CN116023495B (zh) * | 2022-09-05 | 2023-10-03 | 上海百英生物科技股份有限公司 | 一种抗cd40纳米抗体及其制备方法与应用 |
| US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| KR20250057233A (ko) | 2023-10-20 | 2025-04-29 | 한상진 | 이동식 무선 자동 제습기 |
| WO2025129007A1 (en) * | 2023-12-15 | 2025-06-19 | Werewool Inc. | Soy alginate fibers |
| US20250276092A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025184603A2 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5247069A (en) | 1986-06-13 | 1993-09-21 | Oncogen | Ligands and methods for augmenting B-cell proliferation |
| US5182368A (en) | 1986-06-13 | 1993-01-26 | Ledbetter Jeffrey A | Ligands and methods for augmenting B-cell proliferation |
| US5506126A (en) | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
| IL104684A0 (en) | 1992-02-14 | 1993-06-10 | Bristol Myers Squibb Co | The cd40cr receptor and ligands therefor |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| ES2222463T3 (es) | 1993-12-23 | 2005-02-01 | Immunex Corporation | Uso de anticuerpos monoclonales o ligandos oligomericos solubles en la fabricacion de un medicamento para la prevencion o tratamiento de trastornos neoplasicos. |
| EP0892643B2 (en) | 1996-03-20 | 2009-09-02 | Bristol-Myers Squibb Company | Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| EP1322383B9 (en) * | 2000-10-02 | 2006-09-06 | Chiron Corporation | Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| ATE447412T1 (de) | 2003-11-04 | 2009-11-15 | Novartis Vaccines & Diagnostic | Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| CN1922316B (zh) * | 2003-12-25 | 2011-03-23 | 协和发酵麒麟株式会社 | 抗cd40抗体突变体 |
| ATE479760T1 (de) | 2004-03-24 | 2010-09-15 | Domantis Ltd | Universelles signalpeptid gas1 |
| WO2006073443A2 (en) | 2004-04-27 | 2006-07-13 | Novartis Vaccines And Diagnostics, Inc. | Antagonist anti-cd40 monoclonal antibodies and methods for their use |
| US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| CN101061140B (zh) * | 2004-09-17 | 2015-07-01 | 多曼蒂斯有限公司 | 单价结合cd40l的组合物和应用方法 |
| AR053579A1 (es) | 2005-04-15 | 2007-05-09 | Genentech Inc | Tratamiento de la enfermedad inflamatoria intestinal (eii) |
| JP2008541758A (ja) | 2005-06-02 | 2008-11-27 | アストラゼネカ エービー | Ｃｄ２０に対する抗体およびその使用 |
| US7812133B2 (en) | 2005-12-16 | 2010-10-12 | Genentech, Inc | Anti-OX40L antibodies and methods using same |
| EP2441838A3 (en) | 2006-01-24 | 2013-07-10 | Domantis Limited | Fusion proteins that contain natural junctions |
| AR060487A1 (es) | 2006-04-21 | 2008-06-18 | Xoma Technology Ltd | Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40 |
| EP1854810A1 (en) | 2006-05-09 | 2007-11-14 | PanGenetics B.V. | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| SG189817A1 (en) * | 2008-04-30 | 2013-05-31 | Immunogen Inc | Potent conjugates and hydrophilic linkers |
| RU2011126338A (ru) * | 2008-11-28 | 2013-01-10 | Эбботт Лэборетриз | Стабильные композиции антител и способы их стабилизации |
| HUE049849T2 (hu) | 2010-03-31 | 2020-10-28 | Boehringer Ingelheim Int | Anti-CD40 antitestek |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| HUE038848T2 (hu) | 2011-04-21 | 2018-11-28 | Bristol Myers Squibb Co | CD40-antagonista antitest polipeptidek |
-
2012
- 2012-04-20 HU HUE12717027A patent/HUE038848T2/hu unknown
- 2012-04-20 AR ARP120101368A patent/AR086360A1/es unknown
- 2012-04-20 SG SG2013078183A patent/SG194561A1/en unknown
- 2012-04-20 MX MX2013011966A patent/MX354243B/es active IP Right Grant
- 2012-04-20 KR KR1020137030492A patent/KR101734614B1/ko not_active Expired - Fee Related
- 2012-04-20 TW TW105121984A patent/TWI598363B/zh not_active IP Right Cessation
- 2012-04-20 ES ES12717027.2T patent/ES2664619T3/es active Active
- 2012-04-20 CA CA2833743A patent/CA2833743A1/en not_active Abandoned
- 2012-04-20 RS RS20180346A patent/RS57087B1/sr unknown
- 2012-04-20 EA EA201391564A patent/EA030851B1/ru not_active IP Right Cessation
- 2012-04-20 HR HRP20180571TT patent/HRP20180571T1/hr unknown
- 2012-04-20 WO PCT/US2012/034519 patent/WO2012145673A1/en not_active Ceased
- 2012-04-20 ME MEP-2018-94A patent/ME03071B/me unknown
- 2012-04-20 US US14/112,049 patent/US9475879B2/en active Active
- 2012-04-20 TW TW101114258A patent/TW201245225A/zh unknown
- 2012-04-20 SI SI201231203T patent/SI2699601T1/en unknown
- 2012-04-20 DK DK12717027.2T patent/DK2699601T3/en active
- 2012-04-20 SM SM20180228T patent/SMT201800228T1/it unknown
- 2012-04-20 CN CN201280030683.4A patent/CN103842382B/zh not_active Expired - Fee Related
- 2012-04-20 JP JP2014506589A patent/JP6114256B2/ja not_active Expired - Fee Related
- 2012-04-20 BR BR112013026828A patent/BR112013026828A2/pt not_active Application Discontinuation
- 2012-04-20 MA MA36322A patent/MA35035B1/fr unknown
- 2012-04-20 CN CN201710070840.9A patent/CN106977604A/zh active Pending
- 2012-04-20 PE PE2013002381A patent/PE20141188A1/es active IP Right Grant
- 2012-04-20 EP EP12717027.2A patent/EP2699601B1/en active Active
- 2012-04-20 KR KR1020177011260A patent/KR101905346B1/ko not_active Expired - Fee Related
- 2012-04-20 NO NO12717027A patent/NO2699601T3/no unknown
- 2012-04-20 MY MYPI2013003839A patent/MY165090A/en unknown
- 2012-04-20 LT LTEP12717027.2T patent/LT2699601T/lt unknown
- 2012-04-20 PL PL12717027T patent/PL2699601T3/pl unknown
- 2012-04-20 PT PT127170272T patent/PT2699601T/pt unknown
- 2012-04-20 EP EP18151812.7A patent/EP3372616A1/en not_active Withdrawn
- 2012-04-20 AU AU2012245309A patent/AU2012245309C1/en not_active Ceased
-
2013
- 2013-09-27 PH PH12013502013A patent/PH12013502013B1/en unknown
- 2013-10-03 IL IL228720A patent/IL228720B/en active IP Right Grant
- 2013-10-11 TN TNP2013000417A patent/TN2013000417A1/fr unknown
- 2013-10-21 CL CL2013003043A patent/CL2013003043A1/es unknown
- 2013-11-05 CO CO13261140A patent/CO6801649A2/es active IP Right Grant
-
2016
- 2016-04-27 AU AU2016202672A patent/AU2016202672B2/en not_active Ceased
- 2016-09-08 US US15/259,828 patent/US10544228B2/en active Active
-
2017
- 2017-01-05 JP JP2017000493A patent/JP2017099391A/ja active Pending
-
2018
- 2018-04-16 CY CY181100398T patent/CY1120637T1/el unknown
-
2019
- 2019-12-20 US US16/723,047 patent/US11136406B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014513953A5 (https=) | ||
| JP2014530611A5 (https=) | ||
| JP2017099391A5 (https=) | ||
| AU2016351710B2 (en) | Improved serum albumin-binding immunoglobulin variable domains | |
| JP2022507741A5 (https=) | ||
| JP2020521458A5 (https=) | ||
| AU2016357460B2 (en) | Improved serum albumin binders | |
| CN108473563B (zh) | 改进的tnf结合剂 | |
| CN102905727B (zh) | Il-17a拮抗剂 | |
| WO2010055366A4 (en) | Anti-human il-21 monoclonal antibodies | |
| TWI585104B (zh) | 基於vl和vhh可變區衍生物的高親和力抗聚集抗體 | |
| TW200831533A (en) | Interleukin-13 binding proteins | |
| CN106573053B (zh) | 干扰素α和ω抗体拮抗剂 | |
| RU2017134274A (ru) | Связывающие tslp белки | |
| JP2019503990A5 (https=) | ||
| JP2014503209A5 (https=) | ||
| TW201031421A (en) | IL-1 binding proteins | |
| JP2018537421A5 (https=) | ||
| TW200911831A (en) | Polypeptides, antibody variable domains & antagonists | |
| WO2015137843A1 (ru) | Анти-il-17-антитела, способ их получения и способ применения | |
| JP2012500020A5 (https=) | ||
| JP2019504822A5 (https=) | ||
| JP2020171311A (ja) | 抗Ｐｒｅ−Ｓ１ ＨＢＶ抗体 | |
| KR20140108520A (ko) | CD1d에 대한 항체 | |
| JP2011518857A5 (https=) |